Citius Pharmaceuticals
CTXR
71 hedge funds and large institutions have $51.1M invested in Citius Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 17 closing their positions.
155% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $553K
53% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 17
0.05% less ownership
Funds ownership: 0.74% → 0.69% (-0.05%)
3% less funds holding
Funds holding: 73 → 71 (-2)
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
42% less capital invested
Capital invested by funds: $87.4M → $51.1M (-$36.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$1.29M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$453K |
| 3 |
State Street
Boston,
Massachusetts
|
+$393K |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$347K |
| 5 |
Two Sigma Investments
New York
|
+$289K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$2.03M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$554K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$481K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$298K |
| 5 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
-$192K |
CTXR Hedge Fund Activity: Q3 2021 in Review
71 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q3 2021, worth a combined $51.1M — down 42% from $87.4M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CTXR and 15 opened new positions — a net loss of 2 holders — while 17 trimmed existing stakes and 26 added.
The largest buyer was Wells Fargo, adding an estimated $1.29M. The largest seller was Renaissance Technologies, cutting an estimated $2.03M.
- 71 institutional investors held Citius Pharmaceuticals (CTXR) as of Q3 2021, down from 73 in Q2 2021.
- Funds reported $51.1M of Citius Pharmaceuticals stock for Q3 2021, down 42% quarter-over-quarter.
- 15 funds opened new Citius Pharmaceuticals positions in Q3 2021 and 17 closed out, a net change of -2 holders.
- The largest Citius Pharmaceuticals buyer in Q3 2021 was Wells Fargo, an estimated $1.29M added.
- The largest Citius Pharmaceuticals seller in Q3 2021 was Renaissance Technologies, an estimated $2.03M sold.
Based on aggregated 13F filings for Q3 2021.